Posted by Site Administrator on April 12, 2013
Antisense Oligonucleotides May be Feasible ALS Therapeutic Strategy
BOSTON, Massachusetts, March 29, 2013 — Published online today in Lancet Neurology, an SOD1-related familial ALS trial under the direction of NEALS researchers Timothy Miller, MD, PhD (Washington University School of Medicine) and Merit Cudkowicz (Massachusetts General Hospital) indicates that antisense oligonucleotide delivery to the central nervous system may [...]
Categories: ALS Community News, ALS News, Clinical Trials, Research News, Treatments
| 
Tags: ALS, ALS community, ALS treatments, amyotrophic lateral sclerosis, antisense oligonucleotide, Bob Stehlin, cerebrospinal fluid (CSF) ALS, ISIS 333611, Isis Pharmaceuticals, Johns Hopkins University, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, Methodist Neurological Institute, MGH Neurological Clinical Research Institute (NCRI), Northeast ALS Consortium (NEALS), PALS, RASCALS Foundation, RNA ALS, Robert A. Stehlin Campaign for ALS, SOD-1, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Timothy Miller, Washington University in St. Louis, Washington University School of Medicine
| 
No comments
Posted by Site Administrator on March 4, 2013
Recognition that the mutations adversely impact regulation of RNA could lead to targeted therapy to correct the problem. The mutation’s location in the prion-like domain might also prove significant. Although the mutations in hnRNPA2B1 or hnRNPA1 appear to be rare, hundreds of other RNA-binding proteins have prion-like domains. Taylor said patients with unexplained neurodegenerative diseases may have mutations in these proteins.
Categories: ALS News, Research News, Treatments
| Tags: Aaron Gitler, Alan Pestronk and Conrad Weihl, Aleksandra Wojtas, Alice Flynn Ford, ALS, ALS community, ALS research, ALS research funding, ALS study, ALS treatments, Amandine Molliex, amyotrophic lateral sclerosis, Anderson Kanagaraj, Athina-Soragia Gkazi, Bob Stehlin, Boston Biomedical Research Institute, Bradley Smith, Brian Freibaum, Bryan Traynor, Christopher Shaw, Colorado State University, Emily Scarborough, Eric Ross, exomes ALS, Germany, hnRNPA1, hnRNPA2B1, Hong Joo Kim, Institute of Psychiatry, J. Paul Taylor, Jack Miller, Jack Pinkus, Jennifer Moore, John Trojanowski, Kevin Boylan, Kyle MacLea, London, Lou Gehrig's disease, Mayo Clinic, Michael Benatar, Michael Kottlors and Janbernd Kirschner, Nam Chul Kim, National Institute of Aging, National Institutes of Health, neurodegenerative diseases, Oliver King, PALS, RASCALS Foundation, RNA metabolism ALS, Robert A. Stehlin Campaign for ALS, Robert Carter, Rosa Rademaker, Simon Topp, Songqing Li, St. Jude Children's Research Hospital, St. Jude Department of Developmental Neurobiology, St. Louis, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, Stanford University School of Medicine, Steven Greenberg, University Children's Hospital Freiburg, University of California-Irvine, University of Miami Miller School of Medicine, University of Pennsylvania, Virginia Kimonis, Washington University Pediatric Cancer Genome Project, Washington University School of Medicine, Yun Li, Zamia Diaz
| No comments
